Marksans Pharma is engaged in the Business of Formulation of pharmaceutical products.
Financial Results:
Marksans Pharma Ltd reported Revenues for Q3FY24 of ₹586.00 Crores up from ₹480.00 Crore year on year, a rise of 22.08%.
Total Expenses for Q3FY24 of ₹478.00 Crores up from ₹418.00 Crores year on year, a rise of 14.35%.
Consolidated Net Profit of ₹83.00 Crores up 33.87% from ₹62.00 Crores in the same quarter of the previous year.
The Earnings per Share is ₹1.84, up 17.20% from ₹1.57 in the same quarter of the previous year.
*It is important to note that the way the results have been accounted for are slightly different than the ones the companies may choose to publish.
*The presented data is automatically generated. It may occasionally generate incorrect information.